Discovery of potent and selective BRD4 inhibitors capable of blocking TLR3-induced acute airway inflammation

Zhiqing Liu, Bing Tian, Haiying Chen, Pingyuan Wang, Allan R. Brasier, Jia Zhou

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

A series of diverse small molecules have been designed and synthesized through structure-based drug design by taking advantage of fragment merging and elaboration approaches. Compounds ZL0420 (28) and ZL0454 (35) were identified as potent and selective BRD4 inhibitors with nanomolar binding affinities to bromodomains (BDs) of BRD4. Both of them can be well docked into the acetyl-lysine (KAc) binding pocket of BRD4, forming key interactions including the critical hydrogen bonds with Asn140 directly and Tyr97 indirectly via a H2O molecule. Both compounds 28 and 35 exhibited submicromolar potency of inhibiting the TLR3-dependent innate immune gene program, including ISG54, ISG56, IL-8, and Groβ genes in cultured human small airway epithelial cells (hSAECs). More importantly, they also demonstrated potent efficacy reducing airway inflammation in a mouse model with low toxicity, indicating a proof of concept that BRD4 inhibitors may offer the therapeutic potential to block the viral-induced airway inflammation.

Original languageEnglish (US)
Pages (from-to)450-461
Number of pages12
JournalEuropean Journal of Medicinal Chemistry
Volume151
DOIs
StatePublished - May 10 2018

Fingerprint

Inflammation
Drug Design
Genes
Interleukin-8
Lysine
Hydrogen
Molecules
Epithelial Cells
Merging
Toxicity
Hydrogen bonds
Pharmaceutical Preparations
Therapeutics

Keywords

  • Airway inflammation
  • Bromodomain-containing protein 4 (BRD4)
  • Bromodomains
  • Immune response genes
  • Structure-based drug design

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Organic Chemistry

Cite this

Discovery of potent and selective BRD4 inhibitors capable of blocking TLR3-induced acute airway inflammation. / Liu, Zhiqing; Tian, Bing; Chen, Haiying; Wang, Pingyuan; Brasier, Allan R.; Zhou, Jia.

In: European Journal of Medicinal Chemistry, Vol. 151, 10.05.2018, p. 450-461.

Research output: Contribution to journalArticle

@article{6aefd5e9d8be470386081933910201e8,
title = "Discovery of potent and selective BRD4 inhibitors capable of blocking TLR3-induced acute airway inflammation",
abstract = "A series of diverse small molecules have been designed and synthesized through structure-based drug design by taking advantage of fragment merging and elaboration approaches. Compounds ZL0420 (28) and ZL0454 (35) were identified as potent and selective BRD4 inhibitors with nanomolar binding affinities to bromodomains (BDs) of BRD4. Both of them can be well docked into the acetyl-lysine (KAc) binding pocket of BRD4, forming key interactions including the critical hydrogen bonds with Asn140 directly and Tyr97 indirectly via a H2O molecule. Both compounds 28 and 35 exhibited submicromolar potency of inhibiting the TLR3-dependent innate immune gene program, including ISG54, ISG56, IL-8, and Groβ genes in cultured human small airway epithelial cells (hSAECs). More importantly, they also demonstrated potent efficacy reducing airway inflammation in a mouse model with low toxicity, indicating a proof of concept that BRD4 inhibitors may offer the therapeutic potential to block the viral-induced airway inflammation.",
keywords = "Airway inflammation, Bromodomain-containing protein 4 (BRD4), Bromodomains, Immune response genes, Structure-based drug design",
author = "Zhiqing Liu and Bing Tian and Haiying Chen and Pingyuan Wang and Brasier, {Allan R.} and Jia Zhou",
year = "2018",
month = "5",
day = "10",
doi = "10.1016/j.ejmech.2018.04.006",
language = "English (US)",
volume = "151",
pages = "450--461",
journal = "European Journal of Medicinal Chemistry",
issn = "0223-5234",
publisher = "Elsevier Masson SAS",

}

TY - JOUR

T1 - Discovery of potent and selective BRD4 inhibitors capable of blocking TLR3-induced acute airway inflammation

AU - Liu, Zhiqing

AU - Tian, Bing

AU - Chen, Haiying

AU - Wang, Pingyuan

AU - Brasier, Allan R.

AU - Zhou, Jia

PY - 2018/5/10

Y1 - 2018/5/10

N2 - A series of diverse small molecules have been designed and synthesized through structure-based drug design by taking advantage of fragment merging and elaboration approaches. Compounds ZL0420 (28) and ZL0454 (35) were identified as potent and selective BRD4 inhibitors with nanomolar binding affinities to bromodomains (BDs) of BRD4. Both of them can be well docked into the acetyl-lysine (KAc) binding pocket of BRD4, forming key interactions including the critical hydrogen bonds with Asn140 directly and Tyr97 indirectly via a H2O molecule. Both compounds 28 and 35 exhibited submicromolar potency of inhibiting the TLR3-dependent innate immune gene program, including ISG54, ISG56, IL-8, and Groβ genes in cultured human small airway epithelial cells (hSAECs). More importantly, they also demonstrated potent efficacy reducing airway inflammation in a mouse model with low toxicity, indicating a proof of concept that BRD4 inhibitors may offer the therapeutic potential to block the viral-induced airway inflammation.

AB - A series of diverse small molecules have been designed and synthesized through structure-based drug design by taking advantage of fragment merging and elaboration approaches. Compounds ZL0420 (28) and ZL0454 (35) were identified as potent and selective BRD4 inhibitors with nanomolar binding affinities to bromodomains (BDs) of BRD4. Both of them can be well docked into the acetyl-lysine (KAc) binding pocket of BRD4, forming key interactions including the critical hydrogen bonds with Asn140 directly and Tyr97 indirectly via a H2O molecule. Both compounds 28 and 35 exhibited submicromolar potency of inhibiting the TLR3-dependent innate immune gene program, including ISG54, ISG56, IL-8, and Groβ genes in cultured human small airway epithelial cells (hSAECs). More importantly, they also demonstrated potent efficacy reducing airway inflammation in a mouse model with low toxicity, indicating a proof of concept that BRD4 inhibitors may offer the therapeutic potential to block the viral-induced airway inflammation.

KW - Airway inflammation

KW - Bromodomain-containing protein 4 (BRD4)

KW - Bromodomains

KW - Immune response genes

KW - Structure-based drug design

UR - http://www.scopus.com/inward/record.url?scp=85045033477&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045033477&partnerID=8YFLogxK

U2 - 10.1016/j.ejmech.2018.04.006

DO - 10.1016/j.ejmech.2018.04.006

M3 - Article

VL - 151

SP - 450

EP - 461

JO - European Journal of Medicinal Chemistry

JF - European Journal of Medicinal Chemistry

SN - 0223-5234

ER -